The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
Salvatore CarboneHayley E BillingsleyJustin M CanadaEdoardo BressiBrando RotelliDinesh KadariyaDave L DixonRoshanak MarkleyCory R TrankleRichard CookeKrishnasree RaoKeyur B ShahHoracio Medina de ChazalJuan Guido ChiabrandoAlessandra VecchiéMegan DellVirginia L MihalickRoberta BogaevLinda HartBenjamin W Van TassellRoss ArenaFrancesco S CeliAntonio AbbatePublished in: Diabetes/metabolism research and reviews (2020)
In this small and short-term study of patients with T2DM and HFrEF, interrupted early after only 36 patients, canagliflozin did not improve the primary endpoints of peak VO2 or VE/VCO2 slope compared to sitagliptin, while showing favourable trends observed on several additional surrogate endpoints such as lean peak VO2 , VAT and quality of life.